Trusted Resource for Clinical Trials, Protocols & Progress
Improperly validated equipment can result in unnoticed temperature excursions, leading to product degradation and protocol deviations. Regulatory bodies such as USFDA and CDSCO require documented evidence that equipment is qualified and routinely monitored.
Click to read the full article.
Clinical trial materials—especially biologics, vaccines, and temperature-sensitive compounds—must be maintained within validated storage ranges to preserve potency, safety, and efficacy. A temperature breach, whether during storage or transport, may compromise the IP and must be thoroughly documented and investigated.
Click to read the full article.
A Destruction Certificate is a formal record confirming that a batch or quantity of Investigational Products has been destroyed according to regulatory standards. It is issued by the approved destruction vendor or facility and must be traceable to the IP’s origin, condition, and chain of custody.
Click to read the full article.
Moving IPs across borders for destruction is more than a logistics task. It involves compliance with:
Click to read the full article.
Timely IP returns support both operational efficiency and regulatory adherence. Delays or improper returns can result in:
Click to read the full article.
Destruction of IPs involves regulatory, ethical, and environmental obligations. Selecting an unqualified vendor can result in:
Click to read the full article.
An auditable trail enables transparency and traceability from IP receipt to final destruction. It protects the sponsor, CRO, and investigator from regulatory risk while meeting global expectations set by agencies such as the EMA and USFDA.
Click to read the full article.
Environmental regulations aim to minimize the impact of pharmaceutical waste on ecosystems, water supplies, and human health. Improper disposal can result in:
Click to read the full article.
The destruction of expired or unused IP must be documented, traceable, and verifiable. Regulatory bodies like the USFDA, EMA, and Health Canada require clear procedures for handling returned or surplus investigational materials, especially if they are controlled substances, temperature-sensitive, or hazardous.
Click to read the full article.
Returned IP documentation ensures that all clinical trial drugs distributed to sites are accounted for. Inadequate or missing records can result in:
Click to read the full article.
